All News

IgG4.criteria.jpg

Inebilizumab for Treatment of IgG4-Related Disease

d Jack Cush, MD

Inebilizumab is an monoclonal antibody that targets and depletes CD19+ B cells and has been studied in adults with IgG4-related disease.

Read Article
eyes

Phase 2b Study of Ianalumab in Sjögren's

d Jack Cush, MD

A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD).

Read Article
US.knee_.jpg

ICYMI: Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care

d Jiha Lee, MD

Unlike traditional imaging techniques, MSUS can be easily used at the point-of-care and offers high-resolution images of joints, tendons, and soft tissues, facilitating the early detection of inflammation and structural damage. On Saturday, November 16th at the ACR Convergence 2024, Dr. Veena Ranganath, Dr. Gurjit Kaeley, and Dr. Catherine Bakewell will present the “Proposed ACR Guidance for Use of Musculoskeletal Ultrasound in Rheumatoid and Psoriatic Arthritis.” This is the first update in a decade since the 2012 ACR guidance on the reasonable use of MSUS in rheumatology clinical practice.

Read Article
AI

Will the Robots Save Ultrasound?

d David Liew, FRACP

Despite all its benefits, ultrasound’s daily clinical use remains the domain of only a subset of interested rheumatologists. If the benefits are so clear, then why is it not universal? In the late-breaking oral abstracts at ACR Convergence, the final abstract presentation was from the Danish rheumatologists behind ARTHUR and DIANA: the robot which holds the MSK ultrasound probe, and the artificial intelligence brains which empowers it. Perhaps the robots will save us?

Read Article
Rheumatoid,RA,nodules,damage

ICYMI: Shifting Trends in Initial RA Treatment Approaches

d Caoilfhionn Marie Connolly, MD

A recent study by Sparks et al reveals evolving trends in DMARD usage for rheumatoid arthritis over two decades in the United States. This retrospective analysis evaluated 407,728 DMARD initiation episodes among 229,365 unique patients from 2001 to 2021.

Read Article
DEA and the Department of Health and Human Services (HHS) has extended current telemedicine (TM) flexibilities through end 2025. MDs may Rx meds via TM (including narcotics) without in-office visits. https://t.co/C8lyB5feXg https://t.co/eSjYCnu02Y

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR24 IL-17 Topic Panel: Advancing Care with IL-17 Pathway Insights https://t.co/t9QQDYIrda

Links:

Dr. John Cush RheumNow ( View Tweet)

#ACR24: Rheumatology Roundup https://t.co/0DMcpsAZce https://t.co/JvMnfAt3EP

Links:

Dr. John Cush RheumNow ( View Tweet)
Diagnostic Delays in PsA Despite the remarkable expansion of the therapeutic armamentarium for psoriatic arthritis (PsA), the MONITOR-PsA study (abstract 1456) highlights a persistent and critical issue: delays in diagnosis. https://t.co/83TeIpfutP https://t.co/85qo7F9IPa

Links:

Dr. John Cush RheumNow ( View Tweet)
Off-Label Use of JAK Inhibitors in Orphan Diseases and Other Conditions? The issues surrounding publication bias are real. https://t.co/gIFNjAsoM6 https://t.co/UstQGvJX7H

Links:

Dr. John Cush RheumNow ( View Tweet)
UK study compared 16,634 female RA pts vs 65,448 controls and found all RA women at incr risk for VTE (thrombosis)[aHR=1.52) irrespective of estrogen contraceptives/HRT. Contraceptives did not increase VTE risk (aHR 2.32; 0.92, 5.85, p=0.08) #ACR24 https://t.co/AzBXI0W5dv https://t.co/Q4TaKq2ReC

Links:

Dr. John Cush RheumNow ( View Tweet)
Osteoarthritis (OA) affects 53.2 million in the USA & is projected to rise significantly by 2040. Societal costs are $132 billion ($11,00 per/pt). OA is the 3rd most rapidly rising disability, behind diabetes and dementia. https://t.co/n3Rwjjsio3 https://t.co/FPDWd6gEpi

Links:

Dr. John Cush RheumNow ( View Tweet)
Primary Hypophosphatemia (HYPOPH) - Japan study 50,136 adults w/ 424,434 alk phosphatase (ALP) tests. Persistent HYPOPH seen in 0.54% (273) due to cancer(30%), steroids(21%), DMARDs (16%). Unexplained HYPOPH had pain, muscle weakness, fatigue & could have primary HYPOPH… https://t.co/8RbSnhS3vl https://t.co/NdRIA4oREr
Dr. John Cush RheumNow ( View Tweet)
ACR24 JAK/TYK Topic Panel https://t.co/xTDnwjEXE6

Links:

Dr. John Cush RheumNow ( View Tweet)

J&J has submitted 2 supplemental BLAs applying for FDA approval of guselkumab( Tremfya) for use in juvenile plaque psoriasis & juvenile (>5-6 yrs age) psoriatic arthritis based on several phase 3 RCTs. https://t.co/dAkH219pzN https://t.co/R9yJCSOVJa

Links:

Dr. John Cush RheumNow ( View Tweet)
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/ASErsKTNQ6 https://t.co/d1BRW92vju

Links:

Dr. John Cush RheumNow ( View Tweet)
In a phase II DBRPCT, Cenerimod (sphingosine-1-phosphate recptr modulator) was not shown effective (vs PBO) at 12 mos in active, SLE pts. CARE study enrolled 427 SLE pts who were randomized to Placebo or 3 different doses of CEN - primary endpoint was not met.… https://t.co/AR6NsEsv8S https://t.co/i89ANl5dai
Dr. John Cush RheumNow ( View Tweet)
Ozempic will change rheumatology @drdavidliew Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/lELDs7Yy5W https://t.co/wuXZR4vkx8
Dr. John Cush RheumNow ( View Tweet)
Dr. Alexi Grom (video) discusses his presentation from ACR 2024, on the 80% success rate of an anti-IFN gamma mAb (emapalumab) when used in 39 Stills disease patients complicated by life-threatening macrophage activation syndrome. https://t.co/kIPmsVXkCP https://t.co/ib9pKEpZ4L

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR and the Paediatric Rheumatology European Society (PReS) and FDA now view systemic juvenile idiopathic arthritis and adult-onset Still’s disease as a single entity — Still’s disease; based on overlapping tests, clinical manifestations, complications & response to biologics… https://t.co/OHfcFymdPx https://t.co/Wm2ciKbMtY
Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×